tbuckley/cabot-search huggingface dataset:
Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion
Authors: Yan Xiu, Qianze Dong, Lin Fu, Aaron Bossler, Xiaobing Tang, Brendan Boyce, Nicholas Borcherding, Mariah Leidinger, José Luis Sardina, Hai-hui Xue, Qingchang Li, Andrew Feldman, Iannis Aifantis, Francesco Boccalatte, Lili Wang, Meiling Jin, Joseph Khoury, Wei Wang, Shimin Hu, Youzhong Yuan, Endi Wang, Ji Yuan, Siegfried Janz, John Colgan, Hasem Habelhah, Thomas Waldschmidt, Markus Müschen, Adam Bagg, Benjamin Darbro, Chen Zhao
Journal: Blood (2019)
Blinatumumab Induces Responses in Extramedulary B-Cell Acute Lymphoid Leukemia (B-ALL) and Lymphoid Blast Crisis Chronic Myelogenous Leukemia (CML), and Rarely Results in CD19 Negative Relapse
Authors: Jamie Koprivnikar, Danielle Marcotulli, Elizabeth Jones, Grace Perry, Yen-Hong Kuo, Joelle Gagnon, Maritess Aviador, Genique Stanislaus, James McCloskey
Journal: Blood (2018)
Abstract 710: Quality of Life Assessment in Yucatan Mini Swine after Myocardial Infarction
Authors: Sherry L Daugherty, Danielle Spencer-Bearham, Andrew Jauregui, Jeremy Winkelman, Laryenth D Lancaster, Kenneth A Fox, Ryan J Avery, Jennifer Koevary, Steven Goldman, Jordan J Lancaster
Journal: Circulation Research (2019)

Introduction: Quality of life assessments (QOL) measurements are valuable in assessing functional class in patients with chronic heart failure (CHF). Yet, limited quantifiable QOL measures are available in pre-clinical animal models of CHF. To address this issue, we developed methods of QOL assessments in mini swine after myocardial infarction (MI). Methods: Quality of life activity was continuously monitored in Yucatan mini-swine using collar-mounted activity monitors (Fitbark 2) and by performing treadmill exercise tests. Activity treadmill data were obtained for 1 month before and 1 month following MI. Myocardial infarction was created by 90-minute occlusion-reperfusion of the left anterior descending coronary artery. Infarct size and ventricular volumes were measured with Magnetic Resonance Imaging prior to and 1 month after MI. Results: The swine had an average MI size of 20±3%, with increases in LV end-diastolic volume from 62.8±7.8 to 72.1±7.4 ml, LV end-systolic volume from 22.1±2.7 to 36.6±4.8 ml and a decrease in EF from 65±3% to 49±4%, N=5-6 (P&lt;0.05). The 24/7 total FitBark Activity Scores using area under the curve decreased post MI from 184.5±16.8 to 159.4±19.5, N=7-8 (P&lt;0.01). Conclusions: These data demonstrate the feasibility of measuring quality of life in mini swine after myocardial infarction defined by activity level and treadmill exercise testing. This work establishes the potential basis for presenting quality of life measurements in animals as adjunctive assessment of new treatments for chronic heart failure after myocardial infarction.
Discrepancies in Serum Free Light Chain Assays and Immunofixation for Response Evaluation and Prognostication in Plasma Cell Proliferative Disorders
Authors: Nasir Bakshi, Nahlah AlGhasham, Maha Alharbi, Jalaluddin Bhuiyan, Ghada Elgohary, Fahad Alsharief
Journal: Blood (2011)
Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas
Authors: Hidong Kim, Laura Harper, Thomas M. Habermann, Grzegorz S. Nowakowski, Carrie A. Thompson, Patrick Johnston, Thomas E. Witzig, Cristine Allmer, Matthew J. Maurer, James R. Cerhan, Jason Young, Gita Thanarajasingam
Journal: Blood (2018)
Is Affording Undocumented Immigrants Health Coverage a Radical Proposal?
Authors: Lawrence O. Gostin
Journal: JAMA (2019)

During the Democratic presidential debate on July 31, all 10 candidates raised their hands when asked if they would provide health insurance to undocumented immigrants. Among all Democratic ideas for health reform, this is least popular. A recent poll found that only 38% of respondents approve. The idea drew extensive criticism, which is understandable: Why should the United States provide health coverage for people who don’t have a legal right to be here? Extending coverage could be seen as rewarding individuals who have violated the law.

There are, however, strong reasons to afford health coverage for this population: modest economic costs, safeguarding the public’s health by curbing the spread of infectious diseases, and complying with international law that requires health coverage for migrants. Many countries fail to afford migrants equitable access to health coverage, so adopting a policy of providing undocumented immigrants on par with other residents — integrated into existing federal health insurance programs — would help the United States regain moral leadership, in line with World Health Organization (WHO) and United Nations (UN) guidelines, and potentially save money (discussed below).
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
Authors: Neal E. Ready, Patrick A. Ott, Matthew D. Hellmann, Jon Zugazagoitia, Christine L. Hann, Filippo de Braud, Scott J. Antonia, Paolo A. Ascierto, Victor Moreno, Akin Atmaca, Stefania Salvagni, Matthew Taylor, Asim Amin, D. Ross Camidge, Leora Horn, Emiliano Calvo, Ang Li, Wen Hong Lin, Margaret K. Callahan, David R. Spigel
Journal: Journal of Thoracic Oncology (2019)

Nivolumab monotherapy is approved in the United States for third-line or later metastatic small cell lung cancer based on pooled data from nonrandomized and randomized cohorts of the multicenter, open-label, phase 1/2 trial of nivolumab ± ipilimumab (CheckMate 032; NCT01928394). We report updated results, including long-term overall survival (OS), from the randomized cohort.Patients with small cell lung cancer and disease progression after one to two prior chemotherapy regimens were randomized 3:2 to nivolumab 3 mg/kg every 2 weeks or nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four cycles followed by nivolumab 3 mg/kg every 2 weeks. Patients were stratified by number of prior chemotherapy regimens and treated until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by blinded independent central review.Overall, 147 patients received nivolumab and 96 nivolumab plus ipilimumab. Minimum follow-up for ORR/progression-free survival/safety was 11.9 months (nivolumab) and 11.2 months (nivolumab plus ipilimumab). ORR increased with nivolumab plus ipilimumab (21.9% versus 11.6% with nivolumab; odds ratio: 2.12; 95% confidence interval: 1.06-4.26; p = 0.03). For long-term OS, minimum follow-up was 29.0 months (nivolumab) versus 28.4 months (nivolumab plus ipilimumab); median (95% confidence interval) OS was 5.7 (3.8-7.6) versus 4.7 months (3.1-8.3). Twenty-four-month OS rates were 17.9% (nivolumab) and 16.9% (nivolumab plus ipilimumab). Grade 3 to 4 treatment-related adverse event rates were 12.9% (nivolumab) versus 37.5% (nivolumab plus ipilimumab), and treatment-related deaths were n =1 versus n = 3, respectively.Whereas ORR (primary endpoint) was higher with nivolumab plus ipilimumab versus nivolumab, OS was similar between groups. In each group, OS remained encouraging with long-term follow-up. Toxicities were more common with combination therapy versus nivolumab monotherapy.
Sequential Immunomodulatory Drug (IMiD) and Proteosome Inhibitor Therapy Improves Response Rates in Newly Diagnosed Multiple Myeloma: Preliminary Results From the Myeloma XI Trial
Authors: Charlotte Pawlyn, Faith E. Davies, Walter M Gregory, Alex J Szubert, Sue E Bell, Jacqueline Ouzman, Mark T Drayson, Roger G Owen, Graham H Jackson, Nigel H Russell, Gareth J. Morgan
Journal: Blood (2012)
Developing a cancer-specific trigger tool to identify adverse events using administrative data.
Authors: Saul N. Weingart, Benjamin Koethe, Jason Nelson, Omar Yaghi, David M. Kent, Michael J. Hassett, Allison Lipitz-Snyderman
Journal: Journal of Clinical Oncology (2019)

238 Background: “Trigger tools” identify complications of care and potential patient safety hazards. However, attempts to create triggers that flag treatment-related complications in oncology have been largely unsuccessful. To address this problem, the authors built a set of claims-based oncology-specific triggers based on a promising pilot study conducted at Memorial Sloan-Kettering Cancer Center. Methods: We selected subjects from the OptumLabs data warehouse, a repository of &gt; 160 million de-identified patients drawn from commercial claims. The cohort included patients with breast, colorectal, lung, and prostate cancer undergoing an initial course of cancer-directed therapy from 2008-14. Using ICD and CPT codes, we defined 16 oncology-specific triggers drawn from the pilot study, all with PPVs ≥50%. Triggers included events such as neutropenic fever, abnormal serum potassium or bicarbonate, and initiation of therapeutic anticoagulation. To distinguish treatment-related complications from other comorbidities, we required a logical and temporal relationship between a treatment and the associated trigger. We tabulated the prevalence of cancer triggers by cancer type and metastatic status during a one-year follow up period and created multivariate logistic regression models to examine the association of triggered cases with one-year mortality. Results: The cohort comprised 369,354 unique subjects including 29% with metastatic disease. The prevalence of triggered events was greatest among non-metastatic patients with lung (33%) and colorectal (21%) cancers, and among those with metastatic disease. The most common triggers included abnormal chemistry tests, blood transfusions, hypoxemia, and chest CT following radiation therapy. The mortality rate was substantially higher among patients with at least one trigger compared to patients with none. Experiencing at least one cancer-specific trigger increased the one-year risk of death by 1.69 (95% CI 1.28-2.24). Conclusions: Oncology-specific triggers provide researchers a promising method for studying patient safety in cancer care.
Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis
Authors: Miriam Zidane, Corinna Dressler, Matthew Gaskins, Alexander Nast
Journal: JAMA Dermatology (2019)

<h3>Importance</h3> Systemic psoriasis treatments vary in efficacy and cost but also in time until onset of action. Patients with no response to a first induction treatment are typically switched to another, and some patients require several treatments before they see an improvement. <h3>Objective</h3> To determine the most cost-effective sequence of induction treatment through a comparative time-effectiveness analysis of different systemic treatment sequences currently licensed in Germany for moderate to severe plaque psoriasis. <h3>Design, Setting, and Participants</h3> This time-effectiveness analysis used a decision-analytic model set in the German health care system. The population simulated to receive the treatment sequences consisted of adult men and women with psoriasis vulgaris or plaque type psoriasis eligible for systemic treatment. Systematic reviews were performed to generate model input values. Data were collected from November 1 through December 15, 2017, and analyzed from January through August 2018. <h3>Interventions</h3> Five treatment sequences frequently used in Germany, identified through an online expert survey (response rate, 10 of 15 [66.7%]), and 4 theoretical sequences starting with a biological agent. Treatments included methotrexate sodium (MTX), cyclosporine (CSA), fumaric acid esters (FAE), adalimumab (ADA), ixekizumab (IXE), infliximab (INF), and secukinumab (SEC). <h3>Main Outcomes and Measures</h3> Two health states were defined: responder (patients achieving a Psoriasis Area Severity Index [PASI] ≥75) and nonresponder (PASI &lt;75). Probability values were defined as response rates of PASI-75. Treatment effects were determined by the mean change in Dermatology Life Quality Index (DLQI) score. Time until onset of action was assessed as weeks until 25% of patients reach PASI-75. Individual time-effectiveness ratios were calculated per treatment sequence as time until onset of action (in weeks) per minimally important difference (MID) in DLQI and were subsequently ranked. <h3>Results</h3> Treatment sequences starting with a biological agent, including IXE-INF-SEC (1.4 weeks per DLQI-MID), INF-IXE-SEC (2.05 weeks per DLQI-MID), SEC-IXE-ADA (2.1 weeks per DLQI-MID), and ADA-IXE-SEC (2.8 weeks per DLQI-MID) were more time-effective than frequently used treatment sequences, including MTX-SEC-ADA (6.8 weeks per DLQI-MID), MTX-ADA-IXE (7.0 weeks per DLQI-MID), MTX-ADA-SEC (7.2 weeks per DLQI-MID), MTX-FAE-ADA (10.05 weeks per DLQI-MID), and FAE-MTX-CSA (11.5 weeks per DLQI-MID). The results were robust to deterministic sensitivity analyses. <h3>Conclusions and Relevance</h3> When allocating monetary resources, policy makers and regulators may want to consider time until patients experience an MID in their quality of life as an additional outcome measure. <h3>Trial Registration</h3> PROSPERO Identifier:CRD42017074218
HLA Screening for Dapsone Hypersensitivity in India—A Long Way Ahead
Authors: Anuradha Bishnoi, Keshavamurthy Vinay, Sunil Dogra
Journal: JAMA Dermatology (2019)

To the Editor We congratulate Liu et al1 for their work involving proactive HLA screening to prevent dapsone hypersensitivity syndrome (DHS) in patients with leprosy. Herein, we describe the practical difficulties in translating this screening into clinical practice in India.
Impact of Pretransplant Donor and Recipient Cytomegalovirus Serostatus On Outcome for Multiple Myeloma Patients Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation
Authors: Jean El-Cheikh, Raynier Devillier, Roberto Crocchiolo, Sabine Furst, Boris Calmels, Catherine Faucher, Anne Marie Stoppa, Angela Granata, Claire Oudin, Patrick Ladaique, Claude Lemarie, Geoffroy Venton, Reda Bouabdallah, Christine Zandotti, Pierre Berger, Christian Chabannon, Didier Blaise
Journal: Blood (2012)
ASCO Research Community Forum: Impact on clinical research.
Authors: David Michael Waterhouse, Nicholas J. Robert, Edward S. Kim, Dax Kurbegov, Howard A. Burris III, Michael A. Thompson, Grzegorz S. Nowakowski, Patricia A. Hurley, Courtney Davis, Rogerio Lilenbaum
Journal: Journal of Clinical Oncology (2019)

299 Background: In 2011, ASCO launched a forum for the oncology research community to facilitate and promote the implementation of quality clinical research. The ASCO Research Community Forum (RCF) was created to provide a solution-oriented venue for research sites to address common challenges with conducting clinical trials. It offers in-person and virtual forums and resources to learn and share best practices with peers on a variety of topics, including site quality assessment and improvement, research site operations, and clinical trial access and accrual. Methods: An assessment was performed to measure the ASCO RCF output and to gather information on its potential impact on the cancer community. Results: The ASCO RCF has provided an in-person venue for physicians and research administrators with a steady increase in attendance, from 52 attendees in 2012 to 159 in 2018. Multi-stakeholder meetings and manuscripts have promoted best practices and solutions to address challenges with implementing quality clinical trials. Tools and resources to facilitate best practices and quality improvement at trial sites have been accessed by a range of types of research sites from across the U.S. and internationally. Its web-based library of resources was accessed over 27,000 times in 2018, alone. An online forum was launched in 2019 to provide a new opportunity to connect and impact the research community. Conclusions: The ASCO RCF is a productive and esteemed resource for the cancer research community. In-person and virtual forums, along with practical tools, promote access and accrual to clinical trials by facilitating networking, developing solutions, and providing education and resources. The ASCO RCF impact has extended from community-based oncology practices to larger research networks and academic centers across the U.S. and internationally. Its efforts to promote and facilitate access to quality clinical trials align with the vision and mission of ASCO to conquer cancer through research, education, and promotion of the highest quality patient care.
Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence
Authors: Jean Bousquet, Holger J. Schünemann, Akdis Togias, Claus Bachert, Martina Erhola, Peter W. Hellings, Ludger Klimek, Oliver Pfaar, Dana Wallace, Ignacio Ansotegui, Ioana Agache, Anna Bedbrook, Karl-Christian Bergmann, Mike Bewick, Philippe Bonniaud, Sinthia Bosnic-Anticevich, Isabelle Bossé, Jacques Bouchard, Louis-Philippe Boulet, Jan Brozek, Guy Brusselle, Moises A. Calderon, Walter G. Canonica, Luis Caraballo, Vicky Cardona, Thomas Casale, Lorenzo Cecchi, Derek K. Chu, Elisio M. Costa, Alvaro A. Cruz, Wienczyslawa Czarlewski, Gennaro D'Amato, Philippe Devillier, Mark Dykewicz, Motohiro Ebisawa, Jean-Louis Fauquert, Wytske J. Fokkens, Joao A. Fonseca, Jean-François Fontaine, Bilun Gemicioglu, Roy Gerth van Wijk, Tari Haahtela, Susanne Halken, Despo Ierodiakonou, Tomohisa Iinuma, Juan-Carlos Ivancevich, Marek Jutel, Igor Kaidashev, Musa Khaitov, Omer Kalayci, Jorg Kleine Tebbe, Marek L. Kowalski, Piotr Kuna, Violeta Kvedariene, Stefania La Grutta, Désirée Larenas-Linnemann, Susanne Lau, Daniel Laune, Lan Le, Philipp Lieberman, Karin C. Lodrup Carlsen, Olga Lourenço, Gert Marien, Pedro Carreiro-Martins, Erik Melén, Enrica Menditto, Hugo Neffen, Gregoire Mercier, Ralph Mosgues, Joaquim Mullol, Antonella Muraro, Leyla Namazova, Ettore Novellino, Robyn O'Hehir, Yoshitaka Okamoto, Ken Ohta, Hae Sim Park, Petr Panzner, Giovanni Passalacqua, Nhan Pham-Thi, David Price, Graham Roberts, Nicolas Roche, Christine Rolland, Nelson Rosario, Dermot Ryan, Boleslaw Samolinski, Mario Sanchez-Borges, Glenis K. Scadding, Mohamed H. Shamji, Aziz Sheikh, Ana-Maria Todo Bom, Sanna Toppila-Salmi, Ioana Tsiligianni, Marylin Valentin-Rostan, Arunas Valiulis, Erkka Valovirta, Maria-Teresa Ventura, Samantha Walker, Susan Waserman, Arzu Yorgancioglu, Torsten Zuberbier
Journal: Journal of Allergy and Clinical Immunology (2019)
Butyrophilin-like 3 Directly Binds a Human Vγ4+ T Cell Receptor Using a Modality Distinct from Clonally-Restricted Antigen
Authors: Carrie R. Willcox, Pierre Vantourout, Mahboob Salim, Iva Zlatareva, Daisy Melandri, Leonor Zanardo, Roger George, Svend Kjaer, Mark Jeeves, Fiyaz Mohammed, Adrian C. Hayday, Benjamin E. Willcox
Journal: Immunity (2019)

Butyrophilin (BTN) and butyrophilin-like (BTNL/Btnl) heteromers are major regulators of human and mouse γδ T cell subsets, but considerable contention surrounds whether they represent direct γδ T cell receptor (TCR) ligands. We demonstrate that the BTNL3 IgV domain binds directly and specifically to a human Vγ4+ TCR, "LES" with an affinity (∼15–25 μM) comparable to many αβ TCR-peptide major histocompatibility complex interactions. Mutations in germline-encoded Vγ4 CDR2 and HV4 loops, but not in somatically recombined CDR3 loops, drastically diminished binding and T cell responsiveness to BTNL3-BTNL8-expressing cells. Conversely, CDR3γ and CDR3δ loops mediated LES TCR binding to endothelial protein C receptor, a clonally restricted autoantigen, with minimal CDR1, CDR2, or HV4 contributions. Thus, the γδ TCR can employ two discrete binding modalities: a non-clonotypic, superantigen-like interaction mediating subset-specific regulation by BTNL/BTN molecules and CDR3-dependent, antibody-like interactions mediating adaptive γδ T cell biology. How these findings might broadly apply to γδ T cell regulation is also examined.
Comparison between Automated Erythrocytopharesis (AECP) and Manual Exchange Transfusion (M-Ex)) in Reducing Hb-S and in Recovery of Acute Chest Syndrome and Other Acute Presentations of Sickle Cell Disease Patients
Authors: Said Yousuf Ahmed, Sameh M. Saleh, Mohamed Shefan Hameed, Ahmed M. Ragheb, Telal M. Abbas, AbdelMunim Fadel, Siddiq Hassan, Hussein S. Baden, Khaled I Tayeb, Nasir Bakshi, Ghaleb El Yamany, Sultan Bejad Alotaibi
Journal: Blood (2018)
A Four-Way Translocation t (1;17; 9; 22) (p?35; q24; q34;q11) in a Newly Diagnosed Chronic Phase CML Patient: A Case Report
Authors: Eloísa Riva, Rosina Fernandez, Adriana Gonzalez, Gonzalo Manrique, Ricardo Germano, Maria de los Angeles Novoa, Virginia Costa, Santiago Pomoli, M. Rosario Uriarte Escuder, Cynthia de Almeida
Journal: Blood (2012)
Outcome of Transformed Fanconi Anaemia Patients after Hematopoietic Stem Cell Transplantation: Analysis on Behalf of European Group for Blood and Marrow Transplantation
Authors: Stefano Giardino, Dirk-Jan Eikema, Regis Peffault De Latour, Yves Bertrand, Mahmoud Aljurf, Abdelghani Tbakhi, Wolfgang Holter, Martin Bornhäsuer, Claudia Rössig, Marco Zecca, Gerard Michel, Arnold Ganser, Boris Afanasiev, Amal Al-Seraihy, Paul Bosman, Maurizio Miano, Filomena Pierri, Maura Faraci, Edoardo Lanino, Antonio M. Risitano, Nicolaus Kröger, Carlo Dufour
Journal: Blood (2018)
Collaboration with commercial payor to eliminate prior authorization.
Authors: Mallika Sharma, Annika Gustafson, Barbara Jagels, Tracy Wong
Journal: Journal of Clinical Oncology (2019)

9 Background: For commercial insurance plans, there is often a requirement to obtain prior-authorization for specific services. Prior-authorization though intended to ensure medical necessity, can cause significant delays in patient care and create an unnecessary administrative burden. It often leads to undue anxiety in patients, dissatisfaction among providers and substantial waste in the system. To increase our efficiency and improve patient and provider experience, we partnered with one of our region’s largest commercial payors to eliminate prior-authorization. Methods: A Lean Six-sigma DMAIC approach was adopted: Define- created a process map. Measure- calculated baseline for prior-authorization denials. Analyze- conducted retrospective analysis to identify areas to improve. Improve- conducted provider training for appropriate imaging guidelines. Control- established internal auditing to check provider compliance. Results: At SCCA, we found that 94.8% of prior-authorizations were approved instantly or after providing more documentation, thus prior-authorization did not add value. Moreover, 2.15% were approved after peer-to-peer review that involves significant administrative burden and delay in care. Only 3% prior-authorizations did not meet medical necessity criteria, major reasons being- PET/CT and CT CAP ordered in combination, or PET/CT ordered without clear justification. 2.46% prior-authorizations led to a patient receiving a letter of denial. SCCA and the payor agreed to eliminate prior-authorizations for all imaging (except PET and PET/CT). This required all ordering providers to attest to completion of training on the NCCN Imaging Appropriate Use Criteria. In addition, a quarterly internal audit was put in place to check provider compliance to NCCN guidelines for ordering Imaging tests. SCCA achieved a 100% provider training completion rate and 100% provider compliance to NCCN guidelines in the first two internal audits. Conclusions: A strong partnership and shared vision with a payor enabled us to eliminate wasteful prior-authorizations. Our high training completion rate and compliance rate implies strong support from our providers and leadership to provide value-based care to our patients.